NPPA fixes retail price of 13 formulations; Details

Written by Ruchika Sharma Published On 2021-02-13T14:20:47+05:30 | Updated On 19 Oct 2023 4:16 PM IST

NPPA fixes retail price of 13 formulations; Details

New Delhi: Through a recent notification, the National Pharmaceutical Pricing Authority(NPPA), Ministry of Chemicals and Fertilizers, Government of India has fixed the price of 13 formulations, including drugs used to treat diabetes, high blood pressure, and heart-related problems.

These include some popular drug brands and combination formulations like Moxifloxacin Eye Drops, Rosuvastatin plus Clopidogrel Tablet, cocktail drug Vildagliptin and Metformin Hydrochloride (SR) Tablet, and Mefanamic acid and Paracetamol Suspension.

Prominent drugmakers like Sun Pharma, Akums Drugs, Pure and Cure Healthcare, and others are involved in manufacturing the formulations mentioned in the list.

In exercise of the powers conferred by paragraphs 5, 11, and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S. O. 701(E) dated 10th March 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit, and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4), and (5) thereof;

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1.	Rosuvastatin + Aspirin Capsule	Each Capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg Aspirin IP 150mg (as enteric coated)	1 Capsule	M/s Sun Pharma Laboratories Limited	8.09
2.	Moxifloxacin Eye Drops	Composition: Moxifloxacin hydrochloride IP eq. to Moxifloxacin 0.5%w/v	1 ML	M/s East African (India) Overseas / M/s Alkem Laboratories Ltd.	21.87
3.	Ascorbic Acid (Vitamin C) + Zinc Chewable Tablet	Each uncoated Chewable tablet contains: Ascorbic Acid IP 100mg Sodium Ascorbate IP 450mg eq. to Ascorbic Acid 400mg Zinc Citrate USP eq. to Elemental Zinc 5mg	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Koye Pharmaceuticals Pvt. Ltd.	3.82
4.	Telmisartan, Cilnidipine and Chlorthalidone Tablet	Each film-coated tablet contains: Telmisartan IP 40mg, Cilnidipine IP 10mg, Chlorthalidone IP 6.25mg	1 Tablet	M/s Synokem Pharmaceuticals Ltd. / M/s Obsurge Biotech Ltd.	11.36
5.	Pantoprazole Dual- Release Gastro- Resistant Tablet	Each Dual-release Gastro-resistant tablet contains: Pantoprazole Sodium IP eq. to Pantoprazole 80mg	1 Tablet	M/s Alkem Health science / M/s Alkem Laboratories Ltd.	16.48
6.	Rosuvastatin + Clopidogrel Tablet	Each Film-coated tablet contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg, Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Sun Pharma Laboratories Limited	16.97

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
7.	Rosuvastatin + Clopidogrel Tablet	Each Film-coated tablet contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg, Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Sun Pharmaceuticals Industries Ltd.	16.97
8.	Mefanamic acid + Paracetamol Suspension (Pyremol-MF)	Each 5ml contains: Mefanamic Acid IP 100mg Paracetamol IP 250mg	1 ML	M/s Vivimed Labs Ltd. /M/s Alembic Pharmaceuticals Lmited	0.66
9.	Vildagliptin + Metformin Hydrochloride (SR) Tablet	Each uncoated bilayered tablet contains: Vildagliptin 50mg, Metformin Hydrochloride IP 500mg (As sustained release form)	1 Tablet	M/s Exemed Pharmaceuticals / M/s Torrent Pharmaceuticals Limited	6.86
10.	Vildagliptin + Metformin Hydrochloride (SR) Tablet	Each uncoated bi-layered tablet contains: Vildagliptin 50mg, Metformin Hydrochloride IP 1000mg (As sustained release form)	1 Tablet	M/s Exemed Pharmaceuticals / M/s Torrent Pharmaceuticals Limited	7.51
11.	Vildagliptin + Metformin Hydrochloride (SR) Tablet	Each uncoated bilayered tablet contains: Vildagliptin 50mg, Metformin Hydrochloride IP 500mg (As sustained release form)	1 Tablet	M/s Mascot Health Series Pvt. Ltd. / M/s Alkem Laboratories Limited	6.86
12.	Vildagliptin + Metformin Hydrochloride (SR) Tablet	Each uncoated bilayered tablet contains: Vildagliptin 50mg, Metformin Hydrochloride IP 1000mg (As sustained release form)	1 Tablet	M/s Mascot Health Series Pvt. Ltd. / M/s Alkem Laboratories Limited	7.51
13.	Azathioprine Tablet	Each film-coated tablet contains: Azathioprine IP 75mg	1 Tablet	M/s RPG Life Sciences Limited	14.17

NPPA in its notification further added;

(a) The manufacturer of the above-mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above-said table.

(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display a price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

(e) The above mentioned retail price is applicable only to the individual manufacturer/marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as maybe applicable, by the concerned manufacturer/marketing companies.

(f) In case the retail price of any of the aforesaid formulations is not complied with, as per the instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

(g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above-said date of notification, stand(s) superseded.

To access the official notification, click on the link below.

https://medicaldialogues.in/pdf_upload/retail-222110.pdf

nppanational pharmaceutical pricing authorityRosuvastatinMetforminVildagliptinClopidogrelMefanamicsun pharmaakums drug

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751